Geron Total Liab vs Other Stockholder Equity Analysis
GERN Stock | USD 4.17 0.11 2.71% |
Geron financial indicator trend analysis is much more than just examining Geron latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Geron is a good investment. Please check the relationship between Geron Total Liab and its Other Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
Total Liab vs Other Stockholder Equity
Total Liab vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Geron Total Liab account and Other Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Geron's Total Liab and Other Stockholder Equity is 0.81. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Geron, assuming nothing else is changed. The correlation between historical values of Geron's Total Liab and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Geron are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Total Liab i.e., Geron's Total Liab and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Other Stockholder Equity
Most indicators from Geron's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Geron current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.At this time, Geron's Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Issuance Of Capital Stock is likely to grow to about 224 M, though Enterprise Value Over EBITDA is likely to grow to (6.63).
Geron fundamental ratios Correlations
Click cells to compare fundamentals
Geron Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Geron fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 165.5M | 270.7M | 226.0M | 190.6M | 394.1M | 413.8M | |
Other Current Liab | 26.6M | 22.3M | 37.0M | 44.6M | 54.1M | 56.8M | |
Total Current Liabilities | 28.2M | 30.9M | 45.5M | 76.7M | 108.1M | 113.5M | |
Total Stockholder Equity | 135.2M | 210.9M | 126.4M | 80.0M | 247.9M | 132.0M | |
Property Plant And Equipment Net | 408K | 658K | 5.4M | 793K | 4.7M | 5.0M | |
Net Debt | (11.4M) | 19.4M | 20.1M | (1.5M) | 15.9M | 16.7M | |
Retained Earnings | (1.1B) | (1.2B) | (1.3B) | (1.4B) | (1.6B) | (1.5B) | |
Accounts Payable | 1.2M | 6.9M | 6.7M | 10.2M | 6.2M | 6.5M | |
Cash | 13.9M | 10.3M | 34.9M | 57.2M | 70.0M | 40.5M | |
Non Current Assets Total | 23.9M | 70.9M | 38.8M | 10.3M | 52.7M | 55.4M | |
Non Currrent Assets Other | 3.9M | 6.8M | 4.8M | 9.5M | 4.7M | 4.5M | |
Cash And Short Term Investments | 139.6M | 196.6M | 183.7M | 173.1M | 333.7M | 350.4M | |
Common Stock Shares Outstanding | 190.2M | 271.5M | 327.6M | 380.8M | 570.6M | 599.2M | |
Liabilities And Stockholders Equity | 165.5M | 270.7M | 226.0M | 190.6M | 394.1M | 413.8M | |
Non Current Liabilities Total | 2.2M | 28.8M | 54.1M | 33.9M | 38.1M | 40.0M | |
Other Current Assets | 2.0M | 2.9M | 1.7M | 4.4M | 6.0M | 4.0M | |
Other Stockholder Equity | 1.2B | 1.4B | 1.4B | 1.5B | 1.8B | 1.9B | |
Total Liab | 30.4M | 59.8M | 99.6M | 110.6M | 146.1M | 153.4M | |
Property Plant And Equipment Gross | 2.9M | 6.0M | 6.0M | 793K | 6.0M | 6.3M | |
Total Current Assets | 141.6M | 199.9M | 187.2M | 180.2M | 341.3M | 358.4M | |
Accumulated Other Comprehensive Income | 132K | 78K | (173K) | (219K) | 185K | 194.3K | |
Net Receivables | 802K | 722K | 1.8M | 3.1M | 1.7M | 1.3M | |
Common Stock | 200K | 310K | 324K | 390K | 545K | 572.3K | |
Other Assets | 964K | 1.5M | 4.8M | 5.4M | 6.2M | 6.5M | |
Common Stock Total Equity | 200K | 310K | 324K | 390K | 448.5K | 470.9K | |
Short Term Investments | 125.7M | 186.4M | 148.9M | 115.9M | 263.7M | 276.9M | |
Property Plant Equipment | 408K | 658K | 650K | 793K | 713.7K | 1.4M | |
Inventory | (802K) | (722K) | (1.4M) | (3.1M) | (2.8M) | (2.7M) | |
Net Tangible Assets | 137.4M | 210.9M | 126.4M | 80.0M | 92.0M | 139.7M | |
Retained Earnings Total Equity | (1.1B) | (1.2B) | (1.3B) | (1.4B) | (1.3B) | (1.3B) | |
Capital Surpluse | 1.2B | 1.4B | 1.4B | 1.5B | 1.7B | 1.3B | |
Long Term Investments | 19.7M | 63.4M | 28.7M | 0.0 | 43.3M | 28.5M | |
Net Invested Capital | 135.2M | 235.0M | 176.2M | 131.2M | 329.9M | 202.6M | |
Net Working Capital | 113.4M | 168.9M | 141.7M | 103.6M | 233.3M | 158.5M | |
Capital Stock | 200K | 310K | 324K | 390K | 545K | 358.4K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.33) | Revenue Per Share 0.047 | Quarterly Revenue Growth 171.384 | Return On Assets (0.30) | Return On Equity (0.69) |
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.